Fiocruz starts tests for the treatment of Spinal Muscular Atrophy
The National Health Surveillance Agency (Anvisa) authorized the Oswaldo Cruz Foundation (Fiocruz) to begin clinical trials on humans of GB221, an advanced gene therapy product aimed at treating Spinal Muscular Atrophy (SMA)